BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29895123)

  • 1. Rhabdomyosarcoma in children - current pathologic and molecular classification.
    Dziuba I; Kurzawa P; Dopierała M; Larque AB; Januszkiewicz-Lewandowska D
    Pol J Pathol; 2018; 69(1):20-32. PubMed ID: 29895123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of rhabdomyosarcoma and its molecular basis.
    Parham DM; Barr FG
    Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma.
    Oda Y; Kohashi K; Yamamoto H; Tamiya S; Kohno K; Kuwano M; Iwamoto Y; Tajiri T; Taguchi T; Tsuneyoshi M
    Cancer Sci; 2008 Apr; 99(4):726-32. PubMed ID: 18377424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.
    Kohashi K; Oda Y; Yamamoto H; Tamiya S; Takahira T; Takahashi Y; Tajiri T; Taguchi T; Suita S; Tsuneyoshi M
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1097-103. PubMed ID: 18386058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
    Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
    Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
    Smith LM; Anderson JR; Coffin CM
    Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
    Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
    Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O6-methylguanine-DNA methyltransferase activity and promoter methylation status in pediatric rhabdomyosarcoma.
    Yeager ND; Dolan ME; Gastier JM; Gross TG; Delaney S; Frick J; Ruymann FB; Ewesuedo R
    J Pediatr Hematol Oncol; 2003 Dec; 25(12):941-7. PubMed ID: 14663276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myc oncogene expression and nude mouse tumorigenicity and metastasis formation are higher in alveolar than embryonal rhabdomyosarcoma cell lines.
    Kouraklis G; Triche TJ; Wesley R; Tsokos M
    Pediatr Res; 1999 Apr; 45(4 Pt 1):552-8. PubMed ID: 10203148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
    Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
    J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Childhood rhabdomyosarcoma: new insight on biology and treatment.
    Huh WW; Skapek SX
    Curr Oncol Rep; 2010 Nov; 12(6):402-10. PubMed ID: 20820958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
    Nishimura R; Takita J; Sato-Otsubo A; Kato M; Koh K; Hanada R; Tanaka Y; Kato K; Maeda D; Fukayama M; Sanada M; Hayashi Y; Ogawa S
    Cancer Sci; 2013 Jul; 104(7):856-64. PubMed ID: 23578105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes.
    Bridge JA; Liu J; Qualman SJ; Suijkerbuijk R; Wenger G; Zhang J; Wan X; Baker KS; Sorensen P; Barr FG
    Genes Chromosomes Cancer; 2002 Mar; 33(3):310-21. PubMed ID: 11807989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.
    Krsková L; Mrhalová M; Sumerauer D; Kodet R
    Virchows Arch; 2006 Apr; 448(4):449-58. PubMed ID: 16365729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Strategy for Pediatric Paratesticular Rhabdomyosarcoma Based on Chimeric Gene Assessment.
    Unno R; Mizuno K; Ito Y; Etani T; Okada A; Kawai N; Yasui T; Saitoh S; Hayashi Y
    Urology; 2016 Sep; 95():187-9. PubMed ID: 27017905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.